Adtalem Global Education is Tuesday's IBD Stock Of The Day as the leading provider of health care education, which has bet on artificial intelligence to help train health care professionals, traded just below a traditional buy point in stock market action.
Based in Chicago, Adtalem offers a range of academic programs aligned with health care industry needs. With nearly 10,000 employees and its network of institutions, Adtalem serves more than 90,000 students. It has a community of about 350,000 alumni, according to the company.
In September, Adtalem partnered with Hippocratic AI to advance health care education using artificial intelligence. Hippocratic AI is building the first large language model that focuses on safety for health care. Through the collaboration, Adtalem aims to integrate nurses' practical experience with the advanced capabilities of artificial intelligence.
Meanwhile, at the Google Cloud Next conference in May, Adtalem's Chief Customer Officer Steven Tom shared examples of Adtalem's AI journey. He highlighted Adtalem's AI-powered digital human and its collaboration with Alphabet's Google on an AI-powered tutor named "Julian" — one of the first large-language-model applications in higher education.
Along with its push into the AI space, Adtalem earnings have rebounded to a 39% gain vs. year-ago levels in the past four quarters. Analysts project the bottom line rising 18% to $5.89 a share in the fiscal year ending in June 2025.
Despite the expected earnings growth, analyst coverage of ATGE has been sparse, according to FactSet analysis. Still, at the end of October, Barrington analysts raised their stock price target to 95 from 90 while BMO Capital hiked its target to 90 from 84.
Adtalem Stock Performance
Adtalem gained about 0.9% to 90.92 during stock market action on Tuesday. The stock advanced more than 4% last week during stock market trade. ATGE stock is building a tight flat base with a traditional 92.93 buy point, according to MarketSurge chart analysis.
Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks
Adtalem's relative strength line, which measures a stock's price performance compared to the S&P 500, is near a record high, signaling the stock is outperforming the broader market. ATGE has advanced about 55% in 2024.
The stock was highlighted on Dec. 20 in an IBD Stock Analysis piece.
Adtalem stock has a robust 95 Composite Rating out of a best-possible 99. Shares also have a 92 Relative Strength Rating and a 97 EPS Rating.
Please follow Kit Norton on X @KitNorton for more coverage.
YOU MAY ALSO LIKE:
Is Tesla Stock A Buy Or A Sell?
Get Full Access To IBD Stock Lists And Ratings
Learning How To Pick Great Stocks? Read Investor's Corner
AI Is Fueling A 'Nuclear Renaissance.' Bill Gates And Jeff Bezos Are In The Mix.
The Lithium Price Cycle Has Bottomed. What To Expect Next For These Stocks.
